Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...
MHC class II molecules are central to the adaptive immune response, serving as the means by which antigen-presenting cells, notably dendritic cells, display processed peptides to CD4+ T cells. This ...
ProImmune Ltd, a global leader in life science reagents and services, today announced the launch of its new ProVE ® SL Self-Loading MHC Class I Monomers. The novel reagents for antigen-specific CD8+ T ...
New findings reveal how cancer manipulates immune pathways and highlight therapeutic strategies to unleash T-cells against even the most resistant tumors. Study: Cancer cells impair monocyte-mediated ...
T cells are pivotal mediators of the adaptive immune response, with cytotoxic CD8+ T lymphocytes recognising peptides displayed by MHC class I molecules. This antigen presentation process involves the ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional CD8 + T cells in patients with pancreatic ductal adenocarcinoma (PDAC), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results